The estimated Net Worth of Thomas C. Harding is at least $56.3 Thousand dollars as of 1 November 2022. Dr Harding owns over 3,555 units of Clovis Oncology Inc stock worth over $309 and over the last 4 years he sold CLVS stock worth over $56,030.
Dr has made over 24 trades of the Clovis Oncology Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 3,555 units of CLVS stock worth $284 on 1 November 2022.
The largest trade he's ever made was exercising 13,916 units of Clovis Oncology Inc stock on 1 March 2022 worth over $1,113. On average, Dr trades about 2,829 units every 29 days since 2020. As of 1 November 2022 he still owns at least 3,864 units of Clovis Oncology Inc stock.
You can see the complete history of Dr Harding stock trades at the bottom of the page.
Dr. Thomas Fuglsang Harding B.Sc., Ph.D. is the Exec. VP & Chief Scientific Officer at Clovis Oncology Inc.
Dr D is 47, he's been the Exec. VP & Chief Scientific Officer of Clovis Oncology Inc since . There are 7 older and no younger executives at Clovis Oncology Inc. The oldest executive at Clovis Oncology Inc is Dr. Gillian C. Ivers-Read BSc, 67, who is the Co-Founder, Exec. VP & Chief Regulatory Officer.
Thomas's mailing address filed with the SEC is C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER, CO, 80301.
Over the last 13 years, insiders at Clovis Oncology Inc have traded over $37,405,827 worth of Clovis Oncology Inc stock and bought 24,337,722 units worth $298,497,645 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Peter J Barris. On average, Clovis Oncology Inc executives and independent directors trade stock every 17 days with the average trade being worth of $8,863. The most recent stock trade was executed by Paul Edward Gross on 1 November 2022, trading 10,248 units of CLVS stock currently worth $820.
Clovis Oncology Inc executives and other stock owners filed with the SEC include: